• 00:00 1.
    index 1
  • 00:30 2.
    Breast Cancer
  • 00:56 3.
    Triple-Negative Breast Cancer(TNBC)
  • 01:29 4.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 02:06 5.
    Circular RNA (CircRNA)
  • 02:23 6.
    Functions of circRNA
  • 02:49 7.
    MicroRNA (miRNA)
  • 03:20 8.
    Aim
  • 04:01 9.
    The expression and prognostic significance of circWAC in TNBC
  • 05:01 10.
    Features of circWAC
  • 06:14 11.
    CircWAC was mainly distributed in the cytoplasm
  • 06:57 12.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 07:35 13.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 08:19 14.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 09:31 15.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 10:11 16.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 11:42 17.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 12:12 18.
    CircWAC regulates PTX resistance by targeting miR-142
  • 13:16 19.
    CircWAC regulates PTX resistance by targeting miR-142
  • 13:45 20.
    WWP1 is the direct target gene of miR-142
  • 14:57 21.
    WWP1 is the direct target gene of miR-142
  • 15:56 22.
    WWP1 is the direct target gene of miR-142
  • 17:24 23.
    The expression and prognostic significance of circWAC in TNBC
  • 17:54 24.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 19:17 25.
    Conclusion
  • 19:51 26.
    Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
  • 20:53 27.
    Thank you for listening.
  • 21:15 28.
    Model for WWP1-mediated PTEN K27-linked polyubiquitination in tumor development and progression
  • 21:23 29.
    PI3K/AKT pathway
  • 21:23 30.
    Slide 29
  • 21:27 31.
    CircWAC had no obvious relationship with cell metastasis and invasion
  • 21:27 32.
    Thank you for listening.
  • 21:27 33.
    Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
  • 21:28 34.
    Conclusion
  • 21:28 35.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 21:29 36.
    The expression and prognostic significance of circWAC in TNBC
  • 21:29 37.
    WWP1 is the direct target gene of miR-142
  • 21:51 38.
    WWP1 is the direct target gene of miR-142
  • 21:58 39.
    WWP1 is the direct target gene of miR-142
  • 23:55 40.
    Model for WWP1-mediated PTEN K27-linked polyubiquitination in tumor development and progression
  • 23:57 41.
    PI3K/AKT pathway
  • 23:58 42.
    Slide 29
  • 23:58 43.
    CircWAC had no obvious relationship with cell metastasis and invasion
  • 23:58 44.
    Thank you for listening.
  • 23:59 45.
    Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
  • 23:59 46.
    Conclusion
  • 23:59 47.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 24:00 48.
    The expression and prognostic significance of circWAC in TNBC
  • 24:00 49.
    WWP1 is the direct target gene of miR-142
  • 24:00 50.
    WWP1 is the direct target gene of miR-142
  • 24:01 51.
    WWP1 is the direct target gene of miR-142
  • 24:01 52.
    CircWAC regulates PTX resistance by targeting miR-142
  • 24:01 53.
    CircWAC regulates PTX resistance by targeting miR-142
  • 24:05 54.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 24:05 55.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 24:05 56.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 24:06 57.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 24:39 58.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 24:40 59.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 24:40 60.
    CircWAC was mainly distributed in the cytoplasm
  • 24:40 61.
    Features of circWAC
  • 24:41 62.
    The expression and prognostic significance of circWAC in TNBC
  • 24:41 63.
    Aim
  • 24:42 64.
    MicroRNA (miRNA)
  • 24:42 65.
    Functions of circRNA
  • 24:42 66.
    Circular RNA (CircRNA)
  • 24:43 67.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 24:43 68.
    Triple-Negative Breast Cancer(TNBC)
  • 25:16 69.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 25:46 70.
    Circular RNA (CircRNA)
  • 25:48 71.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 25:56 72.
    Circular RNA (CircRNA)
  • 26:01 73.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 27:12 74.
    Circular RNA (CircRNA)
  • 27:12 75.
    Functions of circRNA
  • 27:15 76.
    Circular RNA (CircRNA)
  • 27:17 77.
    Functions of circRNA
  • 27:17 78.
    MicroRNA (miRNA)
  • 27:25 79.
    Functions of circRNA
  • 27:46 80.
    MicroRNA (miRNA)
  • 27:47 81.
    Aim
  • 28:50 82.
    The expression and prognostic significance of circWAC in TNBC
  • 28:55 83.
    Features of circWAC
  • 28:56 84.
    CircWAC was mainly distributed in the cytoplasm
  • 28:56 85.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 28:56 86.
    CircWAC was mainly distributed in the cytoplasm
  • 28:58 87.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 29:19 88.
    CircWAC was mainly distributed in the cytoplasm
  • 29:20 89.
    Features of circWAC
  • 29:20 90.
    The expression and prognostic significance of circWAC in TNBC
  • 29:25 91.
    Features of circWAC
  • 29:54 92.
    CircWAC was mainly distributed in the cytoplasm
  • 30:45 93.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 30:45 94.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 30:46 95.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 31:00 96.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 31:00 97.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 31:01 98.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 31:01 99.
    CircWAC regulates PTX resistance by targeting miR-142
  • 31:02 100.
    CircWAC regulates PTX resistance by targeting miR-142
  • 31:02 101.
    WWP1 is the direct target gene of miR-142
  • 31:03 102.
    WWP1 is the direct target gene of miR-142
  • 31:03 103.
    WWP1 is the direct target gene of miR-142
  • 31:05 104.
    WWP1 is the direct target gene of miR-142
  • 31:30 105.
    WWP1 is the direct target gene of miR-142
  • 31:39 106.
    The expression and prognostic significance of circWAC in TNBC
  • 31:40 107.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 31:41 108.
    Conclusion
  • 32:25 109.
    Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
  • 33:46 110.
    Conclusion
  • 33:46 111.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 33:46 112.
    The expression and prognostic significance of circWAC in TNBC
  • 33:47 113.
    WWP1 is the direct target gene of miR-142
  • 33:47 114.
    WWP1 is the direct target gene of miR-142
  • 33:47 115.
    WWP1 is the direct target gene of miR-142
  • 33:48 116.
    CircWAC regulates PTX resistance by targeting miR-142
  • 33:48 117.
    CircWAC regulates PTX resistance by targeting miR-142
  • 33:48 118.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 33:49 119.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 33:49 120.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 33:49 121.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 33:50 122.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 33:50 123.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 33:50 124.
    CircWAC was mainly distributed in the cytoplasm
  • 33:51 125.
    Features of circWAC
  • 33:51 126.
    The expression and prognostic significance of circWAC in TNBC
  • 33:52 127.
    Aim
  • 33:52 128.
    MicroRNA (miRNA)
  • 33:52 129.
    Functions of circRNA
  • 33:53 130.
    Circular RNA (CircRNA)
  • 33:53 131.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 33:53 132.
    Triple-Negative Breast Cancer(TNBC)
  • 33:54 133.
    Breast Cancer
  • 34:48 134.
    Triple-Negative Breast Cancer(TNBC)
  • 34:49 135.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 34:52 136.
    Circular RNA (CircRNA)
  • 34:55 137.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 34:55 138.
    Triple-Negative Breast Cancer(TNBC)
  • 35:00 139.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 35:25 140.
    Triple-Negative Breast Cancer(TNBC)
  • 35:34 141.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 35:35 142.
    Circular RNA (CircRNA)
  • 35:42 143.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 37:20 144.
    Circular RNA (CircRNA)
  • 37:20 145.
    Functions of circRNA
  • 37:22 146.
    Circular RNA (CircRNA)
  • 37:22 147.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 37:26 148.
    Circular RNA (CircRNA)
  • 37:27 149.
    Functions of circRNA
  • 37:29 150.
    MicroRNA (miRNA)
  • 37:30 151.
    Functions of circRNA
  • 37:42 152.
    Circular RNA (CircRNA)
  • 37:43 153.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 37:56 154.
    Circular RNA (CircRNA)
  • 37:57 155.
    Functions of circRNA
  • 37:57 156.
    MicroRNA (miRNA)
  • 37:58 157.
    Aim
  • 38:01 158.
    MicroRNA (miRNA)
  • 38:07 159.
    Functions of circRNA
  • 38:08 160.
    Circular RNA (CircRNA)
  • 38:08 161.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 39:03 162.
    Triple-Negative Breast Cancer(TNBC)
  • 40:37 163.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 40:44 164.
    Circular RNA (CircRNA)
  • 41:00 165.
    Functions of circRNA
  • 41:00 166.
    MicroRNA (miRNA)
  • 41:01 167.
    Aim
  • 42:19 168.
    The expression and prognostic significance of circWAC in TNBC
  • 42:28 169.
    Features of circWAC
  • 43:47 170.
    CircWAC was mainly distributed in the cytoplasm
  • 43:48 171.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 43:48 172.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 43:49 173.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 44:20 174.
    CircWAC was mainly distributed in the cytoplasm
  • 44:21 175.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 44:21 176.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 44:22 177.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 44:22 178.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 44:22 179.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 44:23 180.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 44:23 181.
    CircWAC regulates PTX resistance by targeting miR-142
  • 44:23 182.
    CircWAC regulates PTX resistance by targeting miR-142
  • 44:24 183.
    WWP1 is the direct target gene of miR-142
  • 44:24 184.
    WWP1 is the direct target gene of miR-142
  • 44:24 185.
    WWP1 is the direct target gene of miR-142
  • 44:25 186.
    The expression and prognostic significance of circWAC in TNBC
  • 44:25 187.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 44:26 188.
    Conclusion
  • 44:26 189.
    Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
  • 45:20 190.
    Conclusion
  • 45:20 191.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 45:20 192.
    The expression and prognostic significance of circWAC in TNBC
  • 45:21 193.
    WWP1 is the direct target gene of miR-142
  • 45:21 194.
    WWP1 is the direct target gene of miR-142
  • 45:22 195.
    WWP1 is the direct target gene of miR-142
  • 45:22 196.
    CircWAC regulates PTX resistance by targeting miR-142
  • 45:22 197.
    CircWAC regulates PTX resistance by targeting miR-142
  • 45:23 198.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 45:23 199.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 45:23 200.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 45:24 201.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 45:29 202.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 45:32 203.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 45:34 204.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 45:37 205.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 45:56 206.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 45:56 207.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 45:57 208.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 45:57 209.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 45:58 210.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 45:59 211.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 45:59 212.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 45:59 213.
    CircWAC regulates PTX resistance by targeting miR-142
  • 46:00 214.
    CircWAC regulates PTX resistance by targeting miR-142
  • 46:02 215.
    CircWAC regulates PTX resistance by targeting miR-142
  • 46:02 216.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 46:03 217.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 46:03 218.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 46:03 219.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 46:33 220.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 46:34 221.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 46:34 222.
    CircWAC was mainly distributed in the cytoplasm
  • 46:35 223.
    Features of circWAC
  • 46:35 224.
    The expression and prognostic significance of circWAC in TNBC
  • 46:36 225.
    Aim
  • 46:37 226.
    MicroRNA (miRNA)
  • 46:49 227.
    Functions of circRNA
  • 46:50 228.
    Circular RNA (CircRNA)
  • 46:51 229.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 48:07 230.
    Triple-Negative Breast Cancer(TNBC)
  • 48:08 231.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 48:08 232.
    Circular RNA (CircRNA)
  • 49:36 233.
    Functions of circRNA
  • 49:37 234.
    MicroRNA (miRNA)
  • 49:38 235.
    Aim
  • 49:38 236.
    The expression and prognostic significance of circWAC in TNBC
  • 49:39 237.
    Features of circWAC
  • 49:39 238.
    CircWAC was mainly distributed in the cytoplasm
  • 49:39 239.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 49:40 240.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 49:40 241.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 49:40 242.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 49:41 243.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 49:41 244.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 49:41 245.
    CircWAC regulates PTX resistance by targeting miR-142
  • 49:42 246.
    CircWAC regulates PTX resistance by targeting miR-142
  • 49:42 247.
    WWP1 is the direct target gene of miR-142
  • 49:42 248.
    WWP1 is the direct target gene of miR-142
  • 49:43 249.
    WWP1 is the direct target gene of miR-142
  • 49:43 250.
    The expression and prognostic significance of circWAC in TNBC
  • 49:44 251.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 49:45 252.
    Conclusion
  • 49:45 253.
    Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
  • 56:02 254.
    ** after 20221101 林俐妤seminar.pptx
  • 索引
  • 筆記
  • 討論
  • 全螢幕
20221031_lab meeting_俐妤
長度: 56:45, 瀏覽: 331, 最近修訂: 2022-10-31
    上一篇 下一篇
    • 00:00 1.
      index 1
    • 00:30 2.
      Breast Cancer
    • 00:56 3.
      Triple-Negative Breast Cancer(TNBC)
    • 01:29 4.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 02:06 5.
      Circular RNA (CircRNA)
    • 02:23 6.
      Functions of circRNA
    • 02:49 7.
      MicroRNA (miRNA)
    • 03:20 8.
      Aim
    • 04:01 9.
      The expression and prognostic significance of circWAC in TNBC
    • 05:01 10.
      Features of circWAC
    • 06:14 11.
      CircWAC was mainly distributed in the cytoplasm
    • 06:57 12.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 07:35 13.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 08:19 14.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 09:31 15.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 10:11 16.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 11:42 17.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 12:12 18.
      CircWAC regulates PTX resistance by targeting miR-142
    • 13:16 19.
      CircWAC regulates PTX resistance by targeting miR-142
    • 13:45 20.
      WWP1 is the direct target gene of miR-142
    • 14:57 21.
      WWP1 is the direct target gene of miR-142
    • 15:56 22.
      WWP1 is the direct target gene of miR-142
    • 17:24 23.
      The expression and prognostic significance of circWAC in TNBC
    • 17:54 24.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 19:17 25.
      Conclusion
    • 19:51 26.
      Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
    • 20:53 27.
      Thank you for listening.
    • 21:15 28.
      Model for WWP1-mediated PTEN K27-linked polyubiquitination in tumor development and progression
    • 21:23 29.
      PI3K/AKT pathway
    • 21:23 30.
      Slide 29
    • 21:27 31.
      CircWAC had no obvious relationship with cell metastasis and invasion
    • 21:27 32.
      Thank you for listening.
    • 21:27 33.
      Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
    • 21:28 34.
      Conclusion
    • 21:28 35.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 21:29 36.
      The expression and prognostic significance of circWAC in TNBC
    • 21:29 37.
      WWP1 is the direct target gene of miR-142
    • 21:51 38.
      WWP1 is the direct target gene of miR-142
    • 21:58 39.
      WWP1 is the direct target gene of miR-142
    • 23:55 40.
      Model for WWP1-mediated PTEN K27-linked polyubiquitination in tumor development and progression
    • 23:57 41.
      PI3K/AKT pathway
    • 23:58 42.
      Slide 29
    • 23:58 43.
      CircWAC had no obvious relationship with cell metastasis and invasion
    • 23:58 44.
      Thank you for listening.
    • 23:59 45.
      Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
    • 23:59 46.
      Conclusion
    • 23:59 47.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 24:00 48.
      The expression and prognostic significance of circWAC in TNBC
    • 24:00 49.
      WWP1 is the direct target gene of miR-142
    • 24:00 50.
      WWP1 is the direct target gene of miR-142
    • 24:01 51.
      WWP1 is the direct target gene of miR-142
    • 24:01 52.
      CircWAC regulates PTX resistance by targeting miR-142
    • 24:01 53.
      CircWAC regulates PTX resistance by targeting miR-142
    • 24:05 54.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 24:05 55.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 24:05 56.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 24:06 57.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 24:39 58.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 24:40 59.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 24:40 60.
      CircWAC was mainly distributed in the cytoplasm
    • 24:40 61.
      Features of circWAC
    • 24:41 62.
      The expression and prognostic significance of circWAC in TNBC
    • 24:41 63.
      Aim
    • 24:42 64.
      MicroRNA (miRNA)
    • 24:42 65.
      Functions of circRNA
    • 24:42 66.
      Circular RNA (CircRNA)
    • 24:43 67.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 24:43 68.
      Triple-Negative Breast Cancer(TNBC)
    • 25:16 69.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 25:46 70.
      Circular RNA (CircRNA)
    • 25:48 71.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 25:56 72.
      Circular RNA (CircRNA)
    • 26:01 73.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 27:12 74.
      Circular RNA (CircRNA)
    • 27:12 75.
      Functions of circRNA
    • 27:15 76.
      Circular RNA (CircRNA)
    • 27:17 77.
      Functions of circRNA
    • 27:17 78.
      MicroRNA (miRNA)
    • 27:25 79.
      Functions of circRNA
    • 27:46 80.
      MicroRNA (miRNA)
    • 27:47 81.
      Aim
    • 28:50 82.
      The expression and prognostic significance of circWAC in TNBC
    • 28:55 83.
      Features of circWAC
    • 28:56 84.
      CircWAC was mainly distributed in the cytoplasm
    • 28:56 85.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 28:56 86.
      CircWAC was mainly distributed in the cytoplasm
    • 28:58 87.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 29:19 88.
      CircWAC was mainly distributed in the cytoplasm
    • 29:20 89.
      Features of circWAC
    • 29:20 90.
      The expression and prognostic significance of circWAC in TNBC
    • 29:25 91.
      Features of circWAC
    • 29:54 92.
      CircWAC was mainly distributed in the cytoplasm
    • 30:45 93.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 30:45 94.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 30:46 95.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 31:00 96.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 31:00 97.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 31:01 98.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 31:01 99.
      CircWAC regulates PTX resistance by targeting miR-142
    • 31:02 100.
      CircWAC regulates PTX resistance by targeting miR-142
    • 31:02 101.
      WWP1 is the direct target gene of miR-142
    • 31:03 102.
      WWP1 is the direct target gene of miR-142
    • 31:03 103.
      WWP1 is the direct target gene of miR-142
    • 31:05 104.
      WWP1 is the direct target gene of miR-142
    • 31:30 105.
      WWP1 is the direct target gene of miR-142
    • 31:39 106.
      The expression and prognostic significance of circWAC in TNBC
    • 31:40 107.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 31:41 108.
      Conclusion
    • 32:25 109.
      Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
    • 33:46 110.
      Conclusion
    • 33:46 111.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 33:46 112.
      The expression and prognostic significance of circWAC in TNBC
    • 33:47 113.
      WWP1 is the direct target gene of miR-142
    • 33:47 114.
      WWP1 is the direct target gene of miR-142
    • 33:47 115.
      WWP1 is the direct target gene of miR-142
    • 33:48 116.
      CircWAC regulates PTX resistance by targeting miR-142
    • 33:48 117.
      CircWAC regulates PTX resistance by targeting miR-142
    • 33:48 118.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 33:49 119.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 33:49 120.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 33:49 121.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 33:50 122.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 33:50 123.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 33:50 124.
      CircWAC was mainly distributed in the cytoplasm
    • 33:51 125.
      Features of circWAC
    • 33:51 126.
      The expression and prognostic significance of circWAC in TNBC
    • 33:52 127.
      Aim
    • 33:52 128.
      MicroRNA (miRNA)
    • 33:52 129.
      Functions of circRNA
    • 33:53 130.
      Circular RNA (CircRNA)
    • 33:53 131.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 33:53 132.
      Triple-Negative Breast Cancer(TNBC)
    • 33:54 133.
      Breast Cancer
    • 34:48 134.
      Triple-Negative Breast Cancer(TNBC)
    • 34:49 135.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 34:52 136.
      Circular RNA (CircRNA)
    • 34:55 137.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 34:55 138.
      Triple-Negative Breast Cancer(TNBC)
    • 35:00 139.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 35:25 140.
      Triple-Negative Breast Cancer(TNBC)
    • 35:34 141.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 35:35 142.
      Circular RNA (CircRNA)
    • 35:42 143.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 37:20 144.
      Circular RNA (CircRNA)
    • 37:20 145.
      Functions of circRNA
    • 37:22 146.
      Circular RNA (CircRNA)
    • 37:22 147.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 37:26 148.
      Circular RNA (CircRNA)
    • 37:27 149.
      Functions of circRNA
    • 37:29 150.
      MicroRNA (miRNA)
    • 37:30 151.
      Functions of circRNA
    • 37:42 152.
      Circular RNA (CircRNA)
    • 37:43 153.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 37:56 154.
      Circular RNA (CircRNA)
    • 37:57 155.
      Functions of circRNA
    • 37:57 156.
      MicroRNA (miRNA)
    • 37:58 157.
      Aim
    • 38:01 158.
      MicroRNA (miRNA)
    • 38:07 159.
      Functions of circRNA
    • 38:08 160.
      Circular RNA (CircRNA)
    • 38:08 161.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 39:03 162.
      Triple-Negative Breast Cancer(TNBC)
    • 40:37 163.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 40:44 164.
      Circular RNA (CircRNA)
    • 41:00 165.
      Functions of circRNA
    • 41:00 166.
      MicroRNA (miRNA)
    • 41:01 167.
      Aim
    • 42:19 168.
      The expression and prognostic significance of circWAC in TNBC
    • 42:28 169.
      Features of circWAC
    • 43:47 170.
      CircWAC was mainly distributed in the cytoplasm
    • 43:48 171.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 43:48 172.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 43:49 173.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 44:20 174.
      CircWAC was mainly distributed in the cytoplasm
    • 44:21 175.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 44:21 176.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 44:22 177.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 44:22 178.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 44:22 179.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 44:23 180.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 44:23 181.
      CircWAC regulates PTX resistance by targeting miR-142
    • 44:23 182.
      CircWAC regulates PTX resistance by targeting miR-142
    • 44:24 183.
      WWP1 is the direct target gene of miR-142
    • 44:24 184.
      WWP1 is the direct target gene of miR-142
    • 44:24 185.
      WWP1 is the direct target gene of miR-142
    • 44:25 186.
      The expression and prognostic significance of circWAC in TNBC
    • 44:25 187.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 44:26 188.
      Conclusion
    • 44:26 189.
      Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
    • 45:20 190.
      Conclusion
    • 45:20 191.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 45:20 192.
      The expression and prognostic significance of circWAC in TNBC
    • 45:21 193.
      WWP1 is the direct target gene of miR-142
    • 45:21 194.
      WWP1 is the direct target gene of miR-142
    • 45:22 195.
      WWP1 is the direct target gene of miR-142
    • 45:22 196.
      CircWAC regulates PTX resistance by targeting miR-142
    • 45:22 197.
      CircWAC regulates PTX resistance by targeting miR-142
    • 45:23 198.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 45:23 199.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 45:23 200.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 45:24 201.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 45:29 202.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 45:32 203.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 45:34 204.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 45:37 205.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 45:56 206.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 45:56 207.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 45:57 208.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 45:57 209.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 45:58 210.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 45:59 211.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 45:59 212.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 45:59 213.
      CircWAC regulates PTX resistance by targeting miR-142
    • 46:00 214.
      CircWAC regulates PTX resistance by targeting miR-142
    • 46:02 215.
      CircWAC regulates PTX resistance by targeting miR-142
    • 46:02 216.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 46:03 217.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 46:03 218.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 46:03 219.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 46:33 220.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 46:34 221.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 46:34 222.
      CircWAC was mainly distributed in the cytoplasm
    • 46:35 223.
      Features of circWAC
    • 46:35 224.
      The expression and prognostic significance of circWAC in TNBC
    • 46:36 225.
      Aim
    • 46:37 226.
      MicroRNA (miRNA)
    • 46:49 227.
      Functions of circRNA
    • 46:50 228.
      Circular RNA (CircRNA)
    • 46:51 229.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 48:07 230.
      Triple-Negative Breast Cancer(TNBC)
    • 48:08 231.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 48:08 232.
      Circular RNA (CircRNA)
    • 49:36 233.
      Functions of circRNA
    • 49:37 234.
      MicroRNA (miRNA)
    • 49:38 235.
      Aim
    • 49:38 236.
      The expression and prognostic significance of circWAC in TNBC
    • 49:39 237.
      Features of circWAC
    • 49:39 238.
      CircWAC was mainly distributed in the cytoplasm
    • 49:39 239.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 49:40 240.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 49:40 241.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 49:40 242.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 49:41 243.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 49:41 244.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 49:41 245.
      CircWAC regulates PTX resistance by targeting miR-142
    • 49:42 246.
      CircWAC regulates PTX resistance by targeting miR-142
    • 49:42 247.
      WWP1 is the direct target gene of miR-142
    • 49:42 248.
      WWP1 is the direct target gene of miR-142
    • 49:43 249.
      WWP1 is the direct target gene of miR-142
    • 49:43 250.
      The expression and prognostic significance of circWAC in TNBC
    • 49:44 251.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 49:45 252.
      Conclusion
    • 49:45 253.
      Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
    • 56:02 254.
      ** after 20221101 林俐妤seminar.pptx
    位置
    1. 知識庫
    2. ...
    3. 2022
    資料夾名稱
    2022
    發表人
    林俐妤
    單位
    賴亮全教授
    建立
    2022-10-31 11:50:39
    最近修訂
    2022-10-31 14:25:09
    長度
    56:45

    臺北市仁愛路一段1號10樓1009室

    R1009 10F No1 Sec1 Ren-Ai Rd, Taipei 100233, Taiwan.

    E-mail: llai@ntu.edu.tw

    Tel: 886-2-2312-3456 # 288241

    Lab: 886-2-2393-8235